TuHURA Biosciences, Inc. (HURA): Total Assets
$27.35M
As of 2025-12-31
$31.75M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $27.35M | +37.0% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $19.97M | n/a | 2026-03-31, Balance as of period end |
| 2024-06-30 | $6.20M | n/a | 2024-10-07, Balance as of period end |
| 2023-12-31 | $4.36M | n/a | 2025-03-31, Balance as of period end |
| 2023-06-30 | $3.98M | -75.1% | 2024-10-07, Balance as of period end |
| 2022-06-30 | $15.95M | +17.8% | 2023-09-18, Balance as of period end |
| 2021-06-30 | $13.54M | +361.0% | 2022-09-27, Balance as of period end |
| 2020-06-30 | $2.94M | -27.2% | 2021-09-28, Balance as of period end |
| 2019-06-30 | $4.04M | -42.9% | 2020-09-18, Balance as of period end |
| 2018-06-30 | $7.07M | -10.6% | 2019-09-09, Balance as of period end |
| 2017-06-30 | $7.91M | +24.5% | 2018-09-24, Balance as of period end |
| 2016-06-30 | $6.36M | +146.8% | 2017-09-27, Balance as of period end |
| 2015-06-30 | $2.58M | -48.5% | 2016-09-13, Balance as of period end |
| 2014-06-30 | $5.00M | n/a | 2015-11-16, Balance as of period end |
| 2013-12-31 | $4.32M | n/m | 2014-08-28, Balance as of period end |
| 2012-12-31 | $182.8K | n/a | 2014-08-28, Balance as of period end |
| 2012-06-30 | $1.8K | -83.2% | 2012-12-20, Balance as of period end |
| 2011-06-30 | $10.7K | n/a | 2012-12-20, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $27.35M | +37.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare HURA, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗